Committees

Aims & Scope

The Targeted Organ Neurology Subcommittee:

• Promote cutting-edge pre-clinical science supporting clinical investigations of cell therapies in neurological diseases/critical illnesses.
• Promote the development and implementation of cell-based therapies for neurological diseases/critical illnesses in a careful and considered manner. 
• Provide a forum for communication and data/database sharing between investigators involved in clinical investigations of cell therapies for neurological diseases/critical illnesses.

The Targeted Organ Cardiovascular Subcommittee:

• Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the solid organ targeted therapy pre-clinical/clinical studies category.
• Review the status of the cardiovascular field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies.
• Publish position papers and engage scientific discourse as necessary to advance the field.

Selected Publications

Cardiovascular

'Veni, Vidi, Vici': how to arm your troops in the battlefield of cardiac repair (Cardiovascular Research 2020, 116:e1-e4)

Cell Therapy for Heart Regeneration: Learning from the Past to Build a Brighter Future (Stem Cells Translational Medicine 2018, 7:702-704)

Neurology

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607)

Clinical trials in traumatic brain injury: cellular therapy and outcome measures (Transfusion. 2019 Feb;59(S1):858-868. doi: 10.1111/trf.14834)

Systemic multipotent adult progenitor cells improve long-term neurodevelopmental outcomes after preterm hypoxic-ischemic encephalopathy (Behavioural Brain Research. 2019 Apr; 362: 77-81)

Multipotent Adult Progenitor Cells, but Not Tissue Inhibitor of Matrix Metalloproteinase-3, Increase Tissue Sparing and Reduce Urological Complications following Spinal Cord injury (J Neurotrauma. 2019 May; 36(9): 1416-1427.

Clinical parameters affecting multipotent adult progenitor cells in vitro (Heliyon. 2019 Oct; 5(10): e02532)

Intravenous Cellular Therapies for Acute Ischemic Stroke (Stroke. 2018 May; 49(5): 1058-1065)

Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial (Lancet Neurol. 2017 May; 16(5): 360-368)

Neurology Subcommittee

Co-Chair

Charles S. Cox Jr., MD
January 2018 - Present

Children’s Program in Regenerative Medicine
Houston, United States

Co-Chair

Robert (Willie) Mays, MD
January 2018 - Present

Athersys, Inc.
Cleveland, United States

Members

Ingrid Catz, MSc
Retired
Vancouver, Canada

Cardiovascular Subcommittee

Chair

Massimiliano Gnecchi, MD, PhD
June 2016 - Present

University of Pavia IRCCS Policlinico San Matteo
Pavia, Italy

Members

Hendrick Jan Ankersmit, MD, PD, MBA
Medical University of Vienna
Vienna, Austria

Sveva Bollini, PhD
University of Genova
Genova, Italy